Len is a clinically active therapy that downregulates c-Myc expression in MM.8 In preclinical studies we have also reported that JQ1, a small molecule inhibitor of bromodomain (BRD) 4, can inhibit MYC RNA expression and MM cell growth.28 Moreover, synergistic anti-tumor activity of Len with another BRD inhibitor CPI203 has been reported in BTZ-resistant mantle cell lymphoma.29 Class-I/II HDACi SAHA and valproic acid also inhibit c-Myc expression in Ph1-positive acute leukemia21 and acute myeloid leukemia cells,30 respectively. Here, MYC is linked to acute myeloid leukemia.